Summary
16.81 0.50(3.06%)09/19/2024
Hims & Hers Health Inc (HIMS)
Hims & Hers Health Inc (HIMS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.06 | 6.85 | -1.42 | -34.31 | 4.18 | 157.05 | 66.43 | 66.43 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 16.81 | |
| Open | 17.12 | |
| High | 17.19 | |
| Low | 16.63 | |
| Volume | 3,116,556 | |
| Change | 0.50 | |
| Change % | 3.06 | |
| Avg Volume (20 Days) | 5,558,593 | |
| Volume/Avg Volume (20 Days) Ratio | 0.56 | |
| 52 Week Range | 0.00 - 25.74 | |
| Price vs 52 Week High | -34.69% | |
| Price vs 52 Week Low | inf% | |
| Range | 0.25 | |
| Gap Up/Down | -0.42 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,394 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 11.20 | |
| Book Value | 1.7430 | |
| Earnings Per Share | -0.4350 | |
| EPS Estimate Current Quarter | -0.0600 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.3800 | |
| EPS Estimate Next Year | -0.1500 | |
| Diluted EPS (TTM) | -0.4350 | |
| Revenues | ||
| Profit Marging | -0.3574 | |
| Operating Marging (TTM) | -0.3751 | |
| Return on asset (TTM) | -0.1988 | |
| Return on equity (TTM) | -0.3577 | |
| Revenue TTM | 228,644,992 | |
| Revenue per share TTM | 1.2170 | |
| Quarterly Revenue Growth (YOY) | 0.7950 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 109,450,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.5024 | |
| Revenue Enterprise Value | 25.1922 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 195,536,000 | |
| Shares Float | 114,542,088 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 18.78 | |
| Institutions (%) | 47.72 | |
09/18 15:10 EST - reuters.com
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.
09/18 09:00 EST - businesswire.com
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare, today announced access to the most common compounded GLP-1 subscriptions for as low as $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have.
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare, today announced access to the most common compounded GLP-1 subscriptions for as low as $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have.
09/18 05:00 EST - fool.com
Hims & Hers Acquisition: How Innovation Will Flourish
Buying a new pharmacy will allow Hims & Hers to expand into new markets.
Hims & Hers Acquisition: How Innovation Will Flourish
Buying a new pharmacy will allow Hims & Hers to expand into new markets.
09/17 07:00 EST - fool.com
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
This telemedicine company seems to leapfrog from one hot area in healthcare to another. Its strategy of acquiring members and turning them into paid subscribers is promising.
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
This telemedicine company seems to leapfrog from one hot area in healthcare to another. Its strategy of acquiring members and turning them into paid subscribers is promising.
09/16 18:51 EST - zacks.com
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.
09/16 09:32 EST - seekingalpha.com
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
09/13 15:05 EST - fool.com
Hims & Hers Stock Pops After Massive Acquisition
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
Hims & Hers Stock Pops After Massive Acquisition
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
09/13 10:05 EST - zacks.com
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
09/11 08:50 EST - fool.com
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
09/11 07:50 EST - fool.com
Is Hims & Hers Health the Next Teladoc?
Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
Is Hims & Hers Health the Next Teladoc?
Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
09/10 07:31 EST - marketbeat.com
Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long
Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.
Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long
Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.
09/10 04:20 EST - fool.com
Is Hims & Hers Health Stock a Buy?
Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.
Is Hims & Hers Health Stock a Buy?
Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.
09/05 13:06 EST - zacks.com
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
09/05 04:50 EST - fool.com
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
09/03 16:37 EST - 247wallst.com
Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
09/02 10:01 EST - zacks.com
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
09/01 03:57 EST - fool.com
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
08/31 16:15 EST - fool.com
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
08/29 21:52 EST - fool.com
Why Hims & Hers Health Stock Was Falling This Week
Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.
Why Hims & Hers Health Stock Was Falling This Week
Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.